^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Margenza (margetuximab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)
Published date:
10/09/2018
Excerpt:
HER2+, PD-L1-unselected, 2nd line GEA pts post T progression received Margetuximab (M)…+ Pembrolizumab (P)...ORR was 5 of 8 (62.5%) in ERBB2 amplified/PD-L1+ pts.
DOI:
10.1093/annonc/mdy282.046
Trial ID:
